SC
ALGS icon

SummitTX Capital’s Aligos Therapeutics ALGS Stock Holding History

SummitTX Capital’s Portfolio ALGS Stock Details ALGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-148,799
Closed -$1.11M – 774
2026
Q1 		$1.11M Buy
148,799
+9,375
+7% +$71.1K 0.03% 424
2025
Q4 		$1.3M Buy
+139,424
New +$1.32M 0.04% 371

Other funds holding ALGS

DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

SummitTX Capital's ALGS Position: Q2 2026 in Review

SummitTX Capital sold out of Aligos Therapeutics (ALGS) in Q2 2026, closing a stake of 148,799 shares — an estimated $1.11M sold.

SummitTX Capital first reported a position in ALGS in Q4 2025 and held it in 2 quarters. The position peaked at $1.3M in Q4 2025. 31 funds tracked by Wall St. Rank hold ALGS as of Q2 2026.

  • SummitTX Capital reported no remaining Aligos Therapeutics position as of Q2 2026 after selling out during the quarter.
  • SummitTX Capital sold 148,799 Aligos Therapeutics shares in Q2 2026, an estimated $1.11M.
  • SummitTX Capital first reported a position in Aligos Therapeutics in Q4 2025 and held it in 2 quarters.
  • SummitTX Capital's Aligos Therapeutics position peaked at $1.3M in Q4 2025.
  • 31 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q2 2026.

Based on SummitTX Capital's 13F filing for Q2 2026, filed 14 Aug 2026.